US Stock Movement: Zenas BioPharma surged on October 20, driven by INDIGO Phase III data and Obeximab.

Zenas BioPharma October 20th Surge Interpretation

Keywords: INDIGO Phase III data, Obexelimab

1. On October 12th, the company announced new data from the INDIGO Phase III study of Obexelimab for the treatment of IgG4-related disease: the open-label extension phase showed sustained clinical activity; analysis of the randomized controlled stage showed a significantly lower number of patients with clinically significant cumulative glucocorticoid toxicity at week 52; preliminary findings from a sub-study on vaccine response indicated patients developed vaccine response after treatment intervals.

2. From October 21st to 23rd, the company plans to present seven posters at MSToronto2026, covering updates such as the Orelabrutinib study in relapsed and remitting multiple sclerosis and the Phase III trial design for progressive multiple sclerosis, among other pipeline developments.

(Disclaimer: This content is generated based on publicly available information collected by AI technology. For reference only and does not constitute investment advice.)